Bharat Parenterals share news, announcements and annual reports
NSE: BPLPHARMABSE: 541096Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,912.60.
30 Oct: open ₹2,277.90, high ₹2,295.10, low ₹1,955.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,399 Cr1,597th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 1,124.69
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.21
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.05%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 0.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.50
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,61,73927.6% delivered
Bharat Parenterals share news and announcements
385 announcements, routine notices left out, newest first. Page 2 of 8.
Nov 2025
12 Nov · Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
12 Nov · For The Quarter And Half Year Ended September 30, 2025
12 Nov · Results
7 Nov · Analysts
6 Nov · Board meeting
Meeting on 12 Nov 2025: quarterly results
Sep 2025
27 Sep · Meeting
4 Sep · Intimation Under Regulation 36 Of The SEBI (LODR) Regulations, 2015.
4 Sep · Corporate action
4 Sep · Corporate action
Jul 2025
28 Jul · Results
22 Jul · Board meeting
Meeting on 28 Jul 2025: annual general meeting and quarterly results
Jun 2025
18 Jun · Analysts
May 2025
12 May · THE MANAGEMENT DISCUSSION AND ANAYLSIS FOR THE QUARTER AND YEAR ENDED ON MARCH 31, 2025.
12 May · Management
12 May · Business
12 May · Dividend
12 May · Board meeting
5 May · Board meeting
Meeting on 12 May 2025: final dividend and audited results
Apr 2025
24 Apr · Announcement Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
15 Apr · Disclosure Under Regulation 30 (5) Of The SEBI LODR Regulations, 2015
Feb 2025
Jan 2025
28 Jan · BHARAT PARENTERALS LIMITED SECURES A LARGE INSTITUTIONAL ORDER
23 Jan · Board meeting
Meeting on 3 Feb 2025: quarterly results17 Jan · Management
Dec 2024
Nov 2024
21 Nov · General Announcement About BPL's Subsidiary Lnnoxel Lifesciences In Regard To Out-Licenses Two Molecules To Leading Generic Pharma Mncs Based Out Of The USA